Patent intelligence · US
US 9994566
Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof
Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof
Patent details — US 9994566
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 12, 2018
- Expiration
- Jun 7, 2038
- Claims
- 25
- CPC classes
- A61K, A61K31/4375, A61K31/444, A61P
Quick answer
US 9994566 (Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof) is held by Shenyang Sunshine Pharmaceutical Co., LTD. Status: granted. Granted Jun 12, 2018. Expires Jun 7, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/4375, A61K31/444, A61P, A61P1/00, A61P19/02
More from Shenyang Sunshine Pharmaceutical Co., LTD
Related pharmaceutical patents in our USPTO index.
-
US 12428432
Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
granted -
US 12428389
Diarylamide compound and application thereof
granted -
US 12384853
Anti-HER2/PD1 bispecific antibody
granted -
US 12324812
Glucopyranosyl derivatives and their uses
granted -
US 12319748
Antibody binding to human HER2 and preparation method and use thereof
granted -
US 12312348
RET inhibitors, pharmaceutical compositions and uses thereof
granted -
US 12269886
Tetravalent bispecific antibody against PD-1 and PD-L1
granted -
US 12258317
Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
granted
Frequently asked questions
What is US patent 9994566?
US 9994566 (Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof) is held by Shenyang Sunshine Pharmaceutical Co., LTD. Status: granted. Granted Jun 12, 2018. Expires Jun 7, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9994566?
Shenyang Sunshine Pharmaceutical Co., LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.
When does US 9994566 expire?
Our index shows an expiration date of Jun 7, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.